Webinar to unpack challenges in end-stage kidney disease care

147

Alio and the Hargan Group are to host a webinar “Bending the cost curve in end-stage kidney disease”, covering topics including challenges facing the end-stage kidney disease (ESKD) population and future innovation in kidney health.

The webinar will take place on 12 July at 2pm EDT and features both Alio co-founder and CEO, David Kuraguntla, and former US Deputy Secretary of Health and Human Services, Eric Hargan.

The webinar will discuss a number of timely topics, including the scope and scale of the challenges facing the ESKD population, the evolving reimbursement landscape—expanding on how to pay for remote patient monitoring and artificial intelligence (AI) technologies, the new role for private payors in the kidney sector, innovation in the medical technology sector that address the current challenges in the healthcare system—to prevent hospitalizations and improve patients’ lives, and progress on eliminating barriers and creating the momentum necessary for scalable systemic change.

As the number of people living with ESKD increases across the USA this conversation is all the more important in how innovation can benefit these patient populations in a sustainable and scalable way, Alio said in a press release. With approximately 800,000 patients in the USA living with ESKD, and almost 150,000 new patients diagnosed per year, these dialogues help increase awareness while offering actionable clinical insights to help patients and lower costs.

ESKD patients make up 1% of the Medicare population but account for 7.2% of Medicare spending, or US$37 Billion. The conversation between startup CEO, David Kuraguntla, and former Deputy Secretary Eric Hargan, represents the type of public-private partnership that will not only move the needle from a public policy perspective, but also attract significant investment from the start-up and venture capital community, Alio adds.

Click here for more details and to register for the webinar.

LEAVE A REPLY

Please enter your comment!
Please enter your name here